The New York Times, December 28, 2020
The Maryland biotech Novavax is starting a final, so-called Phase 3 clinical trial in the United States and Mexico for its experimental coronavirus vaccine, the company announced on Monday.
The little-known firm, which has never brought a vaccine to market before, received up to $1.6 billion from the federal government’s Operation Warp Speed this summer to expedite development. The company reported robust results in earlier phases of its trial, showing that the vaccine prompted strong immune responses in monkeys and people.
Continue reading “Novavax is starting the final stage of testing for its vaccine.”